These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3905323)

  • 1. Critical evaluation of thioridazine bioequivalence.
    Barone JA; Colaizzi JL
    Drug Intell Clin Pharm; 1985 Nov; 19(11):847-58. PubMed ID: 3905323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of generic thioridazine drug products--the FDA viewpoint.
    Hamrell MR; Martinez MN; Dighe SV; Parkman PD
    Drug Intell Clin Pharm; 1987 Apr; 21(4):362-72. PubMed ID: 3569040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of bioequivalence of psychotropic drugs and concerns involving product interchange.
    Barone JA; Byerly WG
    J Clin Psychiatry; 1986 Sep; 47 Suppl():28-32. PubMed ID: 2875067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment: Thioridazine bioequivalence.
    Meyer HM
    Drug Intell Clin Pharm; 1986 Apr; 20(4):311-2. PubMed ID: 3698831
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic thioridazine failure.
    Browning G
    Drug Intell Clin Pharm; 1984 Sep; 18(9):738-9. PubMed ID: 6479024
    [No Abstract]   [Full Text] [Related]  

  • 6. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels and half lives of thioridazine and some of its metabolites. II. Low doses in older psychiatric patients.
    Muusze RG; Vanderheeren FA
    Eur J Clin Pharmacol; 1977 Jan; 11(2):141-7. PubMed ID: 837967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physician survey on generic drugs and substitution of critical dose medications.
    Banahan BF; Kolassa EM
    Arch Intern Med; 1997 Oct; 157(18):2080-8. PubMed ID: 9382664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the effect of pharmaceutical formulation on thioridazine absorption.
    Hirst CA; Kaye RC
    J Pharm Pharmacol; 1971 Dec; 23():246S-247S. PubMed ID: 4401505
    [No Abstract]   [Full Text] [Related]  

  • 15. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
    Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
    J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effect and plasma level of thioridazine.
    de Jonghe FE; van der Helm HJ; Schalken HF; Thiel JH
    Acta Psychiatr Scand; 1973; 49(5):535-45. PubMed ID: 4586599
    [No Abstract]   [Full Text] [Related]  

  • 17. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels and half lives of thioridazine and some of its metabolites. I. High doses in young acute schizophrenics.
    Vanderheeren FA; Muusze RG
    Eur J Clin Pharmacol; 1977 Jan; 11(2):135-40. PubMed ID: 320014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood levels of thioridazine and some of its metabolites in psychiatric patients. A preliminary report.
    Buyze G; Egberts PF; Muusze RG; Poslavsky A
    Psychiatr Neurol Neurochir; 1973; 76(3):229-39. PubMed ID: 4725794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.